Novel pharmaceuticals in the treatment of psychosis in Parkinson’s disease

References

• Francis PT, Perry EK. Cholinergic and other neurotransmitter mechanisms in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies. Mov disord 2007;22(Suppl 17):S351-7
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24:197-211
   PubMed Web of Science ®Google Scholar
• Lippa CF. Synaptophysin immunoreactivity in Pick’s disease: comparison with Alzheimer’s disease and dementia with Lewy bodies. Am J Alzheimers Dis Other Demen 2004;19:341-4
   PubMedGoogle Scholar
• Wakabayashi K, Tanji K, Odagiri S, et al. The Lewy body in Parkinson’s disease and related neurodegenerative disorders. Mol Neurobiol 2013;47:495-508
   PubMed Web of Science ®Google Scholar
• Aarsland D, Ballard C, Rongve A, et al. Clinical trials of dementia with Lewy bodies and Parkinson’s disease dementia. Curr Neurol Neurosci Rep 2012;12:492-501
   PubMed Web of Science ®Google Scholar
• McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-72
   PubMed Web of Science ®Google Scholar
• Papapetropoulos S. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol 2006;29:59
   PubMed Web of Science ®Google Scholar
• Wolters EC, Berendse HW. Management of psychosis in Parkinson’s disease. Curr Opin Neurol 2001;14:499-504
   PubMed Web of Science ®Google Scholar
• Goetz CG, Fan W, Leurgans S, et al. The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol 2006;63:713-16
   PubMed Web of Science ®Google Scholar
• Fenelon G, Soulas T, Zenasni F, Cleret de Langavant L. The changing face of Parkinson’s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov disord 2010;25:763-6
   PubMed Web of Science ®Google Scholar
• Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1998;64:533-5
   PubMed Web of Science ®Google Scholar
• Connolly B, Fox SH. Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson’s disease. Neurotherapeutics 2014;11:78-91
   PubMed Web of Science ®Google Scholar
• Fenelon G, Alves G. Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci 2010;289:12-17
   PubMed Web of Science ®Google Scholar
• Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology 2010;75:1270-6
   PubMed Web of Science ®Google Scholar
• Ramirez-Ruiz B, Junque C, Marti MJ, et al. Cognitive changes in Parkinson’s disease patients with visual hallucinations. Dement Geriatr Cogn Disord 2007;23:281-8
   PubMed Web of Science ®Google Scholar
• Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol 2010;67:996-1001
   PubMedGoogle Scholar
• Zhu K, van Hilten JJ, Putter H, Marinus J. Risk factors for hallucinations in Parkinson’s disease: results from a large prospective cohort study. Mov disord 2013;28:755-62
   PubMed Web of Science ®Google Scholar
• Sawada H, Oeda T, Umemura A, et al. Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson’s disease: case-control study. PLoS One 2014;9:e85886
   PubMed Web of Science ®Google Scholar
• Wolters EC. Dopaminomimetic psychosis in Parkinson’s disease patients: diagnosis and treatment. Neurology 1999;52:S10-13
   PubMed Web of Science ®Google Scholar
• Merims D, Shabtai H, Korczyn AD, et al. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease. J Neural Transm 2004;111:1447-53
   PubMed Web of Science ®Google Scholar
• Goetz CG, Pappert EJ, Blasucci LM, et al. Intravenous levodopa in hallucinating Parkinson’s disease patients: high-dose challenge does not precipitate hallucinations. Neurology 1998;50:515-17
   PubMed Web of Science ®Google Scholar
• Poletti M, Perugi G, Logi C, et al. Dopamine agonists and delusional jealousy in Parkinson’s disease: a cross-sectional prevalence study. Mov disord 2012;27:1679-82
   PubMed Web of Science ®Google Scholar
• de Smet Y, Ruberg M, Serdaru M, et al. Confusion, dementia and anticholinergics in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1982;45:1161-4
   PubMed Web of Science ®Google Scholar
• Ballard C, Piggott M, Johnson M, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000;48:868-76
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res 2011;221:564-73
   PubMed Web of Science ®Google Scholar
• Narayanan NS, Rodnitzky RL, Uc EY. Prefrontal dopamine signaling and cognitive symptoms of Parkinson’s disease. Rev Neurosci 2013;24:267-78
   PubMed Web of Science ®Google Scholar
• Parent A, Hazrati LN. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev 1995;20:91-127
   PubMed Web of Science ®Google Scholar
• Huot P, Johnston TH, Darr T, et al. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov disord 2010;25:1399-408
   PubMed Web of Science ®Google Scholar
• Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010;67:416-21
   PubMed Web of Science ®Google Scholar
• Rolland B, Jardri R, Amad A, et al. Pharmacology of hallucinations: several mechanisms for one single symptom? BioMed Res Int 2014;2014:307106
   PubMed Web of Science ®Google Scholar
• Bortolozzi A, Diaz-Mataix L, Scorza MC, et al. The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J Neurochem 2005;95:1597-607
   PubMed Web of Science ®Google Scholar
• Mocci G, Jimenez-Sanchez L, Adell A, et al. Expression of 5-HT2A receptors in prefrontal cortex pyramidal neurons projecting to nucleus accumbens. Potential relevance for atypical antipsychotic action. Neuropharmacology 2014;79:49-58
   PubMed Web of Science ®Google Scholar
• Geyer MA, Vollenweider FX. Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci 2008;29:445-53
   PubMed Web of Science ®Google Scholar
• Janzen J, van ’t Ent D, Lemstra AW, et al. The pedunculopontine nucleus is related to visual hallucinations in Parkinson’s disease: preliminary results of a voxel-based morphometry study. J Neurol 2012;259:147-54
   PubMed Web of Science ®Google Scholar
• Gama RL, Bruin VM, Tavora DG, et al. Structural brain abnormalities in patients with Parkinson’s disease with visual hallucinations: a comparative voxel-based analysis. Brain Cogn 2014;87:97-103
   PubMed Web of Science ®Google Scholar
• Boecker H, Ceballos-Baumann AO, Volk D, et al. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol 2007;64:984-8
   PubMedGoogle Scholar
• Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology 2004;63:1409-16
   PubMed Web of Science ®Google Scholar
• Kiferle L, Ceravolo R, Giuntini M, et al. Caudate dopaminergic denervation and visual hallucinations: evidence from a (123)I-FP-CIT SPECT study. Parkinsonism Relat Disord 2014;20:761-5
   PubMed Web of Science ®Google Scholar
• McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-6
   PubMed Web of Science ®Google Scholar
• Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev 2012;3:CD006504
   PubMed Web of Science ®Google Scholar
• Ballard C, Kahn Z, Corbett A. Treatment of dementia with Lewy bodies and Parkinson’s disease dementia. Drugs Aging 2011;28:769-77
   PubMed Web of Science ®Google Scholar
• van Laar T, De Deyn PP, Aarsland D, et al. Effects of cholinesterase inhibitors in Parkinson’s disease dementia: a review of clinical data. CNS Neurosci Ther 2011;17:428-41
   PubMed Web of Science ®Google Scholar
• Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson’s Disease. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01014858&Search=Search
   Google Scholar
• Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol 2012;72:41-52
   PubMed Web of Science ®Google Scholar
• Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:969-77
   PubMed Web of Science ®Google Scholar
• Marsh L, Biglan K, Gerstenhaber M, Williams JR. Atomoxetine for the treatment of executive dysfunction in Parkinson’s disease: a pilot open-label study. Mov Disord 2009;24:277-82
   PubMed Web of Science ®Google Scholar
• Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010;75:448-55
   PubMed Web of Science ®Google Scholar
• Atomoxetine Treatment for Cognitive Impairment in Parkinson’s Disease (ATM-Cog). Available from: https://clinicaltrials.gov/ct2/results?term=NCT01738191&Search=Search
   Google Scholar
• Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009;361:1268-78
   PubMed Web of Science ®Google Scholar
• Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011;10:415-23
   PubMed Web of Science ®Google Scholar
• Hindle JV. The practical management of cognitive impairment and psychosis in the older Parkinson’s disease patient. J Neural Transm 2013;120:649-53
   PubMed Web of Science ®Google Scholar
• Factor SA, Molho ES, Friedman JH. Risperidone and Parkinson’s disease. Mov Disord 2002;17:221-2
   PubMed Web of Science ®Google Scholar
• Ford B, Lynch T, Greene P. Risperidone in Parkinson’s disease. Lancet 1994;344:681
   PubMed Web of Science ®Google Scholar
• Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000;55:789-94
   PubMed Web of Science ®Google Scholar
• Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002;17:1031-5
   PubMed Web of Science ®Google Scholar
• Friedman JH. Melperone is ineffective in treating Parkinson’s disease psychosis. Mov Disord 2012;27:803-4
   PubMed Web of Science ®Google Scholar
• Pintor L, Valldeoriola F, Bailles E, et al. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol 2012;35:61-6
   PubMed Web of Science ®Google Scholar
• Werner FM, Covenas R. Safety of antipsychotic drugs: focus on therapeutic and adverse effects. Exp Opin Drug Saf 2014: 1-12
   Google Scholar
• Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s disease. Mov Disord 2006;21:2078-81
   PubMed Web of Science ®Google Scholar
• Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. The Parkinson Study Group. N Engl J Med 1999;340:757-63
   PubMed Web of Science ®Google Scholar
• Clozapine in drug-induced psychosis in Parkinson’s disease. The French Clozapine Parkinson Study Group. Lancet 1999;353:2041-2
   PubMed Web of Science ®Google Scholar
• Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75:689-95
   PubMed Web of Science ®Google Scholar
• Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord 2005;20:958-63
   PubMed Web of Science ®Google Scholar
• Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord 2007;22:313-18
   PubMed Web of Science ®Google Scholar
• Shotbolt P, Samuel M, Fox C, David AS. A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease. Neuropsychiatr Dis Treat 2009;5:327-32
   PubMed Web of Science ®Google Scholar
• Kurlan R, Cummings J, Raman R, Thal L. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007;68:1356-63
   PubMed Web of Science ®Google Scholar
• Hack N, Fayad SM, Monari EH, et al. An eight-year clinic experience with clozapine use in a Parkinson’s disease clinic setting. PLoS One 2014;9:e91545
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 2011;11:59-67
   PubMed Web of Science ®Google Scholar
• Friedman JH. Pimavanserin for the treatment of Parkinson’s disease psychosis. Expert Opin Pharmacother 2013;14:1969-75
   PubMed Web of Science ®Google Scholar
• Vanover KE, Weiner DM, Makhay M, et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N’-(4-(2-methylpropyloxy)phen ylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 2006;317:910-18
   PubMed Web of Science ®Google Scholar
• McFarland K, Price DL, Bonhaus DW. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson’s disease. Behav Pharmacol 2011;22:681-92
   PubMed Web of Science ®Google Scholar
• Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014;383:533-40
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacology 2010;35:881-92
   PubMed Web of Science ®Google Scholar
• Godschalx-Dekker JA, Siegers HP. Reduction of parkinsonism and psychosis with mirtazapine: a case report. Pharmacopsychiatry 2014;47:81-3
   PubMed Web of Science ®Google Scholar
• Nagata T, Shinagawa S, Tagai K, Nakayama K. A case in which mirtazapine reduced auditory hallucinations in a patient with Parkinson disease. Int Psychogeriatr 2013;25:1199-201
   PubMed Web of Science ®Google Scholar
• Normann C, Hesslinger B, Frauenknecht S, et al. Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine. Pharmacopsychiatry 1997;30:263-5
   PubMed Web of Science ®Google Scholar
• Meco G, Bernardi S. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:311-13
   PubMed Web of Science ®Google Scholar
• Voon V, Lang AE. Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease. Clin Neuropharmacol 2004;27:90-2
   PubMed Web of Science ®Google Scholar
• Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson’s disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995;45:1305-8
   PubMed Web of Science ®Google Scholar
• Zoldan J, Friedberg G, Goldberg-Stern H, Melamed E. Ondansetron for hallucinosis in advanced Parkinson’s disease. Lancet 1993;341:562-3
   PubMed Web of Science ®Google Scholar
• Eichhorn TE, Brunt E, Oertel WH. Ondansetron treatment of L-dopa-induced psychosis. Neurology 1996;47:1608-9
   PubMed Web of Science ®Google Scholar
• Diederich NJ, Pieri V, Goetz CG. Coping strategies for visual hallucinations in Parkinson’s disease. Mov Disord 2003;18:831-2
   PubMed Web of Science ®Google Scholar
• Ueda S, Koyama K, Okubo Y. Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT 2010;26:111-15
   PubMed Web of Science ®Google Scholar
• Usui C, Hatta K, Doi N, et al. Improvements in both psychosis and motor signs in Parkinson’s disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1704-8
   PubMed Web of Science ®Google Scholar
• Nishioka K, Tanaka R, Shimura H, et al. Quantitative evaluation of electroconvulsive therapy for Parkinson’s disease with refractory psychiatric symptoms. J Neural Transm 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar